Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

Model scores of the 29,894 trials active now.

Model score 17% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (493 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-06-14. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: leftejectionfractionheartventricular
  Phrases that lowered it: participantsvisittabletmalemmhg
• Accepts healthy volunteers: No (raises risk) · Who can join
• Minimum age: 40 (lowers risk) · Who can join
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 68 (lowers risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Sponsor's past trials: 896 (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 0% (lowers risk) · Drug's FDA history
• Sponsor's past termination rate: 7.3% (lowers risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports in the prior 12 months: 0 (raises risk) · Drug's FDA history
• Blinding: quadruple (lowers risk) · Design
• Drug's FAERS reports marked serious: 100% (raises risk) · Drug's FDA history
• Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Spironolactone in the Treatment of Heart Failure NCT04727073 · started 2018 · scored riskier than 86% of active trials terminated
• Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF) NCT03988634 · started 2019 · scored riskier than 84% of active trials completed
• Phase Ib/IIa Trial With AC01 in Patients With HFrEF NCT05642507 · started 2023 · scored riskier than 35% of active trials completed
• Comparison of Eplerenone Versus Spironolactone in Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes NCT01586442 · started 2012 · scored riskier than 64% of active trials completed
• A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation NCT05636176 · started 2023 · scored riskier than 76% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.